19937 results for «»

Filter By

19937 results

The effectiveness and safety of a planned investment procedure in high-risk chronic total occlusions - The INVEST CTO single arm study

03 Nov 2025

Kalaivani Mahadevan and Sofia Papadopoulou provide their take on the INVEST CTO trial, presented by Anja Oksnes at TCT 2025, in San Francisco.

Kalaivani Mahadevan

Author

Kalaivani Mahadevan
Sofia Papadopoulou

Author

Sofia Papadopoulou
INVEST-CTO: Single arm study of a planned investment procedure in high-risk CTO PCI

Long-term follow-up of the PARTNER 3 Low-Risk randomised trial: seven-year clinical and echocardiographic outcomes

27 Oct 2025

Mirvat Alasnag interviews Michael J. Mack on the PARTNER 3 Low-Risk randomised trial he presented at TCT 2025 in San Francisco.

Dr. Mirvat Alasnag

Author

Mirvat Alasnag
Michael Mack

Author

Michael Mack
Long-term follow-up of the PARTNER 3 Low-Risk randomised trial: seven-year clinical and echocardiographic outcomes

Tendyne transcatheter mitral valve system in patients with severe mitral annular calcification: one-year outcomes from the SUMMIT Severe MAC cohort

27 Oct 2025

Luigi Biasco interviews Paul Sorajja about the SUMMIT MAC Pivotal Trial he presented at TCT 2025, in San Francisco.

Luigi Biasco

Author

Luigi Biasco

Author

Paul Sorajja
SUMMIT: 1-year outcomes of Tendyne TMVR for treatment of severe mitral annular calcification

Ten trials from AHA 2025

12 Nov 2025

Alessandro Sticchi provides us with a curated overview of the late-breaking trials he found most relevant for interventional cardiologists from AHA 2025.

Alessandro Sticchi

Author

Alessandro Sticchi
Ten trials from AHA 2025

Sirolimus-eluting iron bioresorbable scaffold in coronary artery disease: two-year results of IRONMAN-II randomised controlled trial

25 Oct 2025

Alex Sticchi interviews Lei Song on the IRONMAN II trial he presented at TCT 2025, in San Francisco.

Alessandro Sticchi

Author

Alessandro Sticchi
Lei Song

Author

Lei Song
IRONMAN II: 2-year outcomes of sirolimus-eluting bioresorbable scaffolds vs. DES

PARTNER 3: transcatheter or surgical aortic-valve replacement in low-risk patients at 7 years

14 Nov 2025

At 7 years, low-risk patients affected by severe symptomatic aortic valve stenosis 1:1 randomly treated by SAPIEN 3 TAVI or surgery showed similar clinical outcomes and late valve durability

Igor Belluschi

Reviewer

Igor Belluschi

Reviewer

Salvatore Brugaletta
PARTNER 3: TAVR or SAVR in low-risk patients at 7 years

Saibal Kar

Thousand Oaks, United States of America

Lukas Stolz

Munich, Germany

Amar Krishnaswamy

Cleveland, United States of America

Fanglin Lu

Shanghai, China

Frederik Verbrugge

Jette, Belgium

Chiara Valentino

London, United Kingdom

Domenico Giovanni Della Rocca

Brussels, Italy

Laura Lupi

Brescia, Italy

Marianne Kokholm

Aarhus, Denmark

Patricia Garcia Teja

Santander, Spain

Laura Lorusso

London, United Kingdom

Edward Hooper

London, United Kingdom

Chiara Barbera

Enna, Italy

Hans-Jörg Hippe

Witten, Germany

Didn’t find what you were looking for?